Skip to main content

Table 2 Response, remission and low disease activity rates by treatment arm at week 30 (pooled data)

From: Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

n/N (%)

Reference IFX IV

CT-P13 IV

CT-P13 SC

Patients achieving a EULAR good response (CRP criteria)

98/259 (37.8%)

165/415 (39.8%)

83/157 (52.9%)

Patients achieving ACR20 response

179/261 (68.6%)

318/418 (76.1%)

142/161 (88.2%)

Patients achieving ACR50 response

103/261 (39.5%)

195/418 (46.7%)

106/161 (65.8%)

Patients achieving ACR70 response

47/261 (18.0%)

97/418 (23.2%)

68/161 (42.2%)

DAS28-CRP

 Patients achieving low disease activity: DAS28-CRP ≤ 3.2

101/259 (39.0%)

166/415 (40.0%)

84/157 (53.5%)

 Patients achieving remission: DAS28-CRP < 2.6

60/259 (23.2%)

101/415 (24.3%)

59/157 (37.6%)

CDAI

 Patients achieving low disease activity: CDAI ≤ 10.0

93/259 (35.9%)

172/416 (41.3%)

92/161 (57.1%)

 Patients achieving remission: CDAI ≤ 2.8

22/259 (8.5%)

50/416 (12.0%)

27/161 (16.8%)

SDAI

 Patients achieving low disease activity: SDAI ≤ 11.0

96/259 (37.1%)

172/415 (41.4%)

89/157 (56.7%)

 Patients achieving remission: SDAI ≤ 3.3

22/259 (8.5%)

53/415 (12.8%)

29/157 (18.5%)

Patients achieving Boolean remission

6/260 (2.3%)

12/416 (2.9%)

12/161 (7.5%)

Patients achieving HAQ-DI MCID (≥ 0.22)

15/261 (5.7%)

36/418 (8.6%)

30/161 (18.6%)

  1. ACR American College of Rheumatology, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28-CRP 28-joint Disease Activity Score based on C-reactive protein, EULAR European League Against Rheumatism, HAQ-DI Health Assessment Questionnaire–Disability Index, IFX infliximab, IV intravenous, MCID minimal clinically important difference, SC subcutaneous, SDAI Simple Disease Activity Index